Patents by Inventor Deyao Li

Deyao Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10919856
    Abstract: A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity IC50 of some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 16, 2021
    Assignee: GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD.
    Inventors: Jiancun Zhang, Kun Wang, Yan Liu, Deyao Li
  • Publication number: 20200246302
    Abstract: Provided are a long-acting prodrug of Rasagiline, which has application in the treatment of Central Nervous System diseases such as Parkinson's disease, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected from each of R1 and R2 is independently selected from H, D, and alkyl; W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from —C(?O)NH—, —NHC(?O)—; R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, —R3a—C(?O)O—R3b, —R3a—OC(?O)—R3b, —R3a—C(?O)NH—R3b, —R3a—NHC(?O)—R3b, —R3a—S(?O)1-2O—R3b and —R3a—OS(?O)1-2—R3b.
    Type: Application
    Filed: August 27, 2018
    Publication date: August 6, 2020
    Inventors: Jiancun ZHANG, Deyao LI, Yiqian ZHOU, Yiwu Wu
  • Publication number: 20200239513
    Abstract: Provided are a long-acting prodrug of Entecavir, preparation method and use thereof, wherein the prodrug of Entecavir has a structure of formula I. The prodrug of Entecavir can be released slowly, sustainably and steady, and converted to active compound of Entecavir to achieve a long-acting effect.
    Type: Application
    Filed: September 29, 2018
    Publication date: July 30, 2020
    Inventors: Jiancun ZHANG, Deyao LI, Yiqian ZHOU, Yiwu Wu, Yan LIU
  • Publication number: 20200207773
    Abstract: Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.
    Type: Application
    Filed: August 15, 2018
    Publication date: July 2, 2020
    Inventors: Yikai WANG, Yang ZHANG, Zhengxia CHEN, Linlin CHEN, Tao FENG, Rongxin HUANG, Qiu LI, Deyao LI, Jikui SUN, Yangyang XU, Jie LI, Jian LI, Shuhui CHEN
  • Publication number: 20190241520
    Abstract: A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity IC50 of some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.
    Type: Application
    Filed: September 5, 2017
    Publication date: August 8, 2019
    Inventors: Jiancun Zhang, Kun Wang, Yan Liu, Deyao Li
  • Publication number: 20190167593
    Abstract: A cyclohexene derivative or pharmaceutically acceptable salt thereof and application thereof, which belongs to the technical field of pharmaceutical technology is provided. The cyclohexene derivative of formula I or pharmaceutically acceptable salt thereof is a new broad-spectrum anti-influenza compound, having a great inhibiting effect on influenza viruses, specifically, it has a high activity to virus strains which is drug-resistant to Oseltamivir, and may be used as a broad-spectrum anti-influenza NA inhibitor effective to Tamiflu drug-resistance, for treating the flu caused by influenza viruses, thereby it is a broad-spectrum anti-influenza drug.
    Type: Application
    Filed: April 27, 2017
    Publication date: June 6, 2019
    Inventors: Jiancun Zhang, Deyao Li, Hong Li, Kun Wang, Yan Liu, Yan Wu, Xing Tang, Jianbo Song
  • Publication number: 20180303810
    Abstract: Provided are a nimodipine water-soluble derivative, and a preparation method and a use thereof, belonging to the field of pharmaceutical chemistry. The nimodipine water-soluble derivative has the structural feature of general formula I and has a relatively high water solubility, and can be converted into nimodipine by an internal enzyme in blood or in the body, so that the nimodipine water-soluble derivative can be used as a nimodipine prodrug and a calcium ion antagonist for treating cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: July 29, 2016
    Publication date: October 25, 2018
    Applicant: Guangzhou Henovcom Bioscience Co., Ltd.
    Inventors: Jiancun Zhang, Deyao Li, Kun Wang, Yan Liu, Yuanchao Zhang